Study Evaluating SCA-136 Tolerability With Dose Titration and Food
Phase 1
Terminated
- Conditions
- Healthy
- Registration Number
- NCT00420706
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
To evaluate whether the tolerability of SCA-136 is improved by dosing with food or by increasing dose amounts in a step-wise fashion.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
- Healthy men or women, aged 18 to 50 years
Exclusion Criteria
- Abnormal vital signs, ECG, or lab results
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method The primary endpoint is the proportion of subjects reporting nausea (based on AEs) over the dosing period.
- Secondary Outcome Measures
Name Time Method